About DNA Script
DNA Script is a company based in Paris (France) founded in 2014 by Xavier Godron. DNA Script has raised $301.69 million across 10 funding rounds from investors including Fidelity Investments, ARE and Agilent. DNA Script offers products and services including ssDNA Oligonucleotides, SYNTAX Platform, and SYNTAX System. DNA Script operates in a competitive market with competitors including Ansa Biotechnologies, Nuclera Nucleics, Twist Bioscience, Mesa Biotech and Nutcracker Therapeutics, among others.
- Headquarter Paris, France
- Founders Xavier Godron
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dna Script
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$301.69 M (USD)
in 10 rounds
-
Latest Funding Round
$4.32 M (USD), Grant
Sep 01, 2023
-
Investors
Fidelity Investments
& 26 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of DNA Script
DNA Script offers a comprehensive portfolio of products and services, including ssDNA Oligonucleotides, SYNTAX Platform, and SYNTAX System.
Synthetic DNA strands for research in mRNA and genomics.
System for rapid, on-demand custom DNA oligo production.
Device enabling in-house DNA synthesis for various applications.
Funding Insights of DNA Script
DNA Script has successfully raised a total of $301.69M across 10 strategic funding rounds. The most recent funding activity was a Grant round of $4.32 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in DNA Script
DNA Script has secured backing from 27 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, ARE and Agilent.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are invested in by sector-agnostic VC fund.
|
Locked | Locked | Locked | |
|
Provider of an investment platform for various stages
|
Locked | Locked | Locked | |
|
Venture capital is provided to biomedical technology startups.
|
Locked | Locked | Locked |
Investor details for DNA Script
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DNA Script
Investment portfolio details for DNA Script
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - DNA Script
Detailed financials for DNA Script
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dna Script Comparisons
Peer comparison for DNA Script
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DNA Script
DNA Script operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ansa Biotechnologies, Nuclera Nucleics, Twist Bioscience, Mesa Biotech and Nutcracker Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
DNA synthesis technology using enzymes is provided.
|
|
| Locked | Locked | Locked |
Desktop bioprinter for genes and proteins production is developed.
|
|
| Locked | Locked | Locked |
Synthetic DNA is synthesized via a semiconductor-based platform.
|
|
| Locked | Locked | Locked |
Point-of-care molecular diagnostic kits are developed and supplied.
|
|
| Locked | Locked | Locked |
mRNA therapeutics are developed via proprietary biochip platforms.
|
Detailed competitors of DNA Script
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dna Script
Complete news archive for DNA Script
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DNA Script
DNA Script was founded in 2014 and raised its 1st funding round 3 years after it was founded.
DNA Script is headquartered in Paris, France.
DNA Script is a funded company, having raised a total of $301.69M across 10 funding rounds to date.
Founded in 2014 in Paris, France, DNA Script operates in the biotechnology sector. A benchtop DNA printer powered by enzymatic technology is developed for nucleic acid synthesis. Outsourced DNA synthesis services are provided, replacing traditional chemical methods with enzymatic approaches. The companys operations focus on enabling on-demand DNA production in laboratory settings across Europe and beyond.
DNA Script's top competitors include Nuclera Nucleics, Twist Bioscience and Ansa Biotechnologies.
DNA Script offers ssDNA Oligonucleotides, SYNTAX Platform, and SYNTAX System.
DNA Script has 27 investors. Key investors include Fidelity Investments, ARE, Agilent, Merck, and T. Rowe Price.